journal article·2022-11-15

Nanoaggregates of Disulfide-Decorated TrxR Inhibitor Promote Cellular Uptake, Selective Targeting, and Antitumor Efficacy

Jing Liu, Youqiao Xu, Haojie Lu, Rong Wang, Zhuolu Xia, Changshun Zhao, Dechun Huang, Feng Jiang, Wei Chen

Langmuir· Volume 38· Issue 45
Publisher page

Abstract

Three self-assembled nanoaggregates (CPUL1-LA NAs, CPUL1-DA NAs, and CPUL1-AA NAs) were constructed through lipoic acid (LA), dithiodipropionic acid (DA), and adipic acid (AA) decorated TrxR inhibitor (CPUL1), respectively. Measurements of DLS, TEM, UV–vis, fluorescence, 1H NMR, ITC, and MTT assays verified disulfide-containing CPUL1-LA NAs and CPUL1-DA NAs spontaneously assembled carrier-free nanoparticles in aqueous solution, which possessed high drug contents, excellent stability, improved cytotoxicity against HUH7 hepatoma cells, and potential biosafety because of low cytotoxicity against L02 normal cells. In contrast, disulfide-free CPUL1-AA NAs happened to aggregate and precipitate after 48 h, which showed distinct instability in aqueous solution. Thus, disulfide units seemed to be crucial for constructing controllable and stable nanoaggregates. While measuring the reduction of nanoaggregates by TrxR/NADPH and GSH/GR/NADPH, cyclic disulfide of LA and linear disulfide of DA were verified to endow the nanoaggregates with targeting ability to respond specifically to TrxR over GSH. Furthermore, by tests of flow cytometry, fluorescence images, and CLSM, both CPUL1-LA NAs and CPUL1-DA NAs displayed a faster cellular uptake characteristic to be internalized by cancer cells and could generate more abundant ROS to induce cell apoptosis than that of free CPUL1, resulting in significantly improved antitumor efficacy against HUH7 cells in vitro.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, P. R. China

Department of Infection Control, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, P. R. China

School of Chemistry and Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210094, P. R. China

Funding

Natural Science Foundation of Jiangsu Province

References (20)

Show source-provided references
1. 10.1038/s41467-022-29136-410.1038/s41467-022-29136-4 ↗
2. 10.1038/s41467-019-10807-810.1038/s41467-019-10807-8 ↗
3. 10.1016/j.ejmech.2016.10.06810.1016/j.ejmech.2016.10.068 ↗
4. 10.1080/14756366.2019.162454110.1080/14756366.2019.1624541 ↗
5. 10.1016/j.bioorg.2021.10473610.1016/j.bioorg.2021.104736 ↗
6. 10.1002/anie.20120841410.1002/anie.201208414 ↗
7. 10.1021/acs.accounts.8b0034010.1021/acs.accounts.8b00340 ↗
8. 10.1016/j.ccr.2020.21330010.1016/j.ccr.2020.213300 ↗
9. 10.1016/j.apsb.2021.08.01210.1016/j.apsb.2021.08.012 ↗
10. 10.1016/j.pmatsci.2021.10091910.1016/j.pmatsci.2021.100919 ↗
11. 10.1002/cmdc.20210063210.1002/cmdc.202100632 ↗
12. 10.1089/ars.2012.501310.1089/ars.2012.5013 ↗
13. 10.1002/anie.20030057310.1002/anie.200300573 ↗
14. 10.1006/bbrc.1996.116510.1006/bbrc.1996.1165 ↗
15. 10.1021/bi802146w10.1021/bi802146w ↗
16. 10.1002/anie.20180105810.1002/anie.201801058 ↗
17. 10.1021/ja408792k10.1021/ja408792k ↗
18. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
19. 10.1016/j.ijpharm.2020.12018410.1016/j.ijpharm.2020.120184 ↗
20. 10.1152/physrev.00026.201310.1152/physrev.00026.2013 ↗